Jump to main content
Jump to site search


A hypoxia-specific and mitochondria-targeted anticancer theranostic agent with high selectivity for cancer cells

Author affiliations

Abstract

Herein, a novel soluble mitochondria-targeted theranostic compound, HMX-1, was presented, which was selectively activated under hypoxia with excellent mitochondria-targeting ability at the cellular level, accompanied by a dramatic increase in the fluorescence intensity. Moreover, its anti-cancer efficiency was certified both in vitro and in vivo.

Graphical abstract: A hypoxia-specific and mitochondria-targeted anticancer theranostic agent with high selectivity for cancer cells

Back to tab navigation

Supplementary files

Publication details

The article was received on 16 Mar 2018, accepted on 03 Apr 2018 and first published on 03 Apr 2018


Article type: Communication
DOI: 10.1039/C8TB00546J
Citation: J. Mater. Chem. B, 2018, Advance Article
  •   Request permissions

    A hypoxia-specific and mitochondria-targeted anticancer theranostic agent with high selectivity for cancer cells

    M. Hu, C. Yang, Y. Luo, F. Chen, F. Yang, S. Yang, H. Chen, Z. Cheng, K. Li and Y. Xie, J. Mater. Chem. B, 2018, Advance Article , DOI: 10.1039/C8TB00546J

Search articles by author

Spotlight

Advertisements